Angiotensin-Converting Enzyme Inhibitors and Metabolic Aging: A Drosophila Perspective
Biomolecules · 2025
DOI: 10.3390/biom15101378 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Denise Vecchie' und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Aging, Drosophila melanogaster. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Aging is characterized by a progressive decline in physiological function that impairs performance and increases vulnerability to disease and mortality. Delaying this deterioration is key to promoting healthy aging. Age-associated functional decline is closely linked to alterations in intermediary metabolism, including disrupted lipid metabolism and impaired mitochondrial function. Counteracting these metabolic changes, particularly those affecting basal metabolic rate and energy utilization, may be a feasible strategy to extend healthspan. The Renin-Angiotensin System (RAS), which controls blood pressure through Angiotensin II, an octapeptide hormone generated from Angiotensin I by Angiotensin-Converting Enzyme (ACE), has been identified as a potential target for aging therapies. ACE inhibitors, such as the commonly prescribed vasodilator lisinopril, have been shown to exert beneficial effects on healthspan. Disentangling their systemic effects from direct cellular actions on intermediary metabolism is challenging in humans but can be pursued in model organisms. Drosophila melanogaster expresses two ortholog of mammalian ACE, Ance and Acer, which have diverged to acquire different functions. Since fundamental cellular processes are evolutionarily conserved and flies have an open circulatory system, Drosophila provides a versatile model for translational studies on ACE inhibition and aging. Recent studies in Drosophila reveal sex-, age-, and genetic background-specific effects of lisinopril on metabolic rates and aging-related organismal phenotypes. Integrating preclinical findings from Drosophila with clinical studies will be essential to define the therapeutic potential of RAS inhibition in extending lifespan and delaying aging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
- Department of Pharmaceutical, Social and Administrative Sciences, Samford University, Birmingham, AL 35229, USA.
- Department of Genetics and Biochemistry and Center for Human Genetics, Clemson University, Greenwood, SC 29646, USA.
ORCID-Profile: Patricia Jumbo-Lucioni, Robert R H Anholt, Maria De Luca
Förderung
- NIA NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Vecchie', D., Faber, V. G., Jumbo-Lucioni, P., Anholt, R. R. H., Mackay, T. F. C., & De Luca, M. (2025). Angiotensin-Converting Enzyme Inhibitors and Metabolic Aging: A Drosophila Perspective. Biomolecules. https://doi.org/10.3390/biom15101378
Vancouver
Vecchie' D, Faber VG, Jumbo-Lucioni P, Anholt RRH, Mackay TFC, De Luca M. Angiotensin-Converting Enzyme Inhibitors and Metabolic Aging: A Drosophila Perspective. Biomolecules. 2025. doi:10.3390/biom15101378
BibTeX
@article{Vecchie2025,
author = {Vecchie', Denise and Faber, Victoria G and Jumbo-Lucioni, Patricia and Anholt, Robert R H and Mackay, Trudy F C and De Luca, Maria},
title = {Angiotensin-Converting Enzyme Inhibitors and Metabolic Aging: A Drosophila Perspective},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15101378}
}
EUVIMED